AstraZeneca (AZN) Tops Q4 EPS by 103c; offers guidance

AstraZeneca (NASDAQ: AZN) reported Q4 EPS of $2.09, $1.03 better than the analyst estimate of $1.06. Revenue for the quarter came in at $14.89 billion versus the consensus estimate of $14.15 billion.

GUIDANCE

Guidance for FY 2025: Total Revenue is expected to increase by a high single-digit percentage and Core EPS is expected to increase by a low double-digit percentage, both at CER

For earnings history and earnings-related data on AstraZeneca (AZN) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• TNL Mediagene faces Nasdaq delisting over bid price and equity rules
• Select Medical stockholders approve buyout by insider-led consortium